Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2004 1
2016 1
2017 3
2020 1
2021 2
2022 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Results by year

Filters applied: . Clear all
Page 1
SMARCA4 biology in alveolar rhabdomyosarcoma.
Bharathy N, Cleary MM, Kim JA, Nagamori K, Crawford KA, Wang E, Saha D, Settelmeyer TP, Purohit R, Skopelitis D, Chang K, Doran JA, Kirschbaum CW, Bharathy S, Crews DW, Randolph ME, Karnezis AN, Hudson-Price L, Dhawan J, Michalek JE, Ciulli A, Vakoc CR, Keller C. Bharathy N, et al. Among authors: cleary mm. Oncogene. 2022 Mar;41(11):1647-1656. doi: 10.1038/s41388-022-02205-0. Epub 2022 Jan 29. Oncogene. 2022. PMID: 35094009 Free PMC article.
EphB4/EphrinB2 therapeutics in Rhabdomyosarcoma.
Randolph ME, Cleary MM, Bajwa Z, Svalina MN, Young MC, Mansoor A, Kaur P, Bult CJ, Goros MW, Michalek JE, Xiang S, Keck J, Krasnoperov V, Gill P, Keller C. Randolph ME, et al. Among authors: cleary mm. PLoS One. 2017 Aug 17;12(8):e0183161. doi: 10.1371/journal.pone.0183161. eCollection 2017. PLoS One. 2017. PMID: 28817624 Free PMC article.
In vitro benchmarking of NF-κB inhibitors.
Harrold AP, Cleary MM, Bharathy N, Lathara M, Berlow NE, Foreman NK, Donson AM, Amani V, Zuercher WJ, Keller C. Harrold AP, et al. Among authors: cleary mm. Eur J Pharmacol. 2020 Apr 15;873:172981. doi: 10.1016/j.ejphar.2020.172981. Epub 2020 Jan 31. Eur J Pharmacol. 2020. PMID: 32014486 Free PMC article.
Defining the Extracellular Matrix of Rhabdomyosarcoma.
Lian X, Bond JS, Bharathy N, Boudko SP, Pokidysheva E, Shern JF, Lathara M, Sasaki T, Settelmeyer T, Cleary MM, Bajwa A, Srinivasa G, Hartley CP, Bächinger HP, Mansoor A, Gultekin SH, Berlow NE, Keller C. Lian X, et al. Among authors: cleary mm. Front Oncol. 2021 Feb 23;11:601957. doi: 10.3389/fonc.2021.601957. eCollection 2021. Front Oncol. 2021. PMID: 33708626 Free PMC article.
NFκB signaling in alveolar rhabdomyosarcoma.
Cleary MM, Mansoor A, Settelmeyer T, Ijiri Y, Ladner KJ, Svalina MN, Rubin BP, Guttridge DC, Keller C. Cleary MM, et al. Dis Model Mech. 2017 Sep 1;10(9):1109-1115. doi: 10.1242/dmm.030882. Dis Model Mech. 2017. PMID: 28883017 Free PMC article.
Sensitization of osteosarcoma to irradiation by targeting nuclear FGFR1.
Kim JA, Berlow NE, Lathara M, Bharathy N, Martin LR, Purohit R, Cleary MM, Liu Q, Michalek JE, Srinivasa G, Cole BL, Chen SD, Keller C. Kim JA, et al. Among authors: cleary mm. Biochem Biophys Res Commun. 2022 Sep 17;621:101-108. doi: 10.1016/j.bbrc.2022.07.002. Epub 2022 Jul 4. Biochem Biophys Res Commun. 2022. PMID: 35820279
Preclinical testing of the glycogen synthase kinase-3β inhibitor tideglusib for rhabdomyosarcoma.
Bharathy N, Svalina MN, Settelmeyer TP, Cleary MM, Berlow NE, Airhart SD, Xiang S, Keck J, Hayden JB, Shern JF, Mansoor A, Lathara M, Srinivasa G, Langenau DM, Keller C. Bharathy N, et al. Among authors: cleary mm. Oncotarget. 2017 Jun 16;8(38):62976-62983. doi: 10.18632/oncotarget.18520. eCollection 2017 Sep 8. Oncotarget. 2017. PMID: 28968964 Free PMC article.
CCR4-bearing T cells participate in autoimmune diabetes.
Kim SH, Cleary MM, Fox HS, Chantry D, Sarvetnick N. Kim SH, et al. Among authors: cleary mm. J Clin Invest. 2002 Dec;110(11):1675-86. doi: 10.1172/JCI15547. J Clin Invest. 2002. PMID: 12464673 Free PMC article.
12 results